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Abstract
AIM: To examine the efficacy of telbivudine (LdT) + 
adefovir (ADV) vs  continuation of lamivudine (LAM) + 
ADV in patients with LAM-resistant chronic hepatitis B 
(CHB) who show a suboptimal response to LAM + ADV.
METHODS: This was a randomized, active-control, 
open-label, single-center, parallel trial. All eligible pa-
tients were enrolled in this study in Severance Hospital, 
Yonsei University College of Medicine, Seoul, South 
Korea, between March 2010 and March 2011. Hepatitis 
Be antigen (HBeAg)-positive CHB patients whose serum 
hepatitis B virus (HBV) DNA remained detectable despite 
at least 6 mo of LAM + ADV therapy were included. En-
rolled patients were randomized to either switching to 
LdT (600 mg/d orally) plus ADV (10 mg/d orally) (LdT 
+ ADV group) or to continuation with LAM (100 mg/d 
orally) plus ADV (10 mg/d orally) (LAM + ADV group), 
and were followed for 48 wk. One hundred and six pa-
tients completed the 48-wk treatment period. Serum 
HBV DNA, HBeAg status, liver biochemistry and safety 
were monitored at baseline and week 12, 24, 36 and 48.
RESULTS: The duration of prior LAM + ADV treatment 
was 18.3 (LdT + ADV) and 14.9 mo (LAM + ADV), re-
spectively (P  = 0.131). No difference was seen in base-
line serum HBV DNA between the two groups [3.66 (LdT 
+ ADV) vs  3.76 (LAM + ADV) log10 IU/mL, P  = 0.729]. 
At week 48, although there was no significant differ-
ence in the mean reduction of serum HBV DNA from 
baseline between LdT + ADV group and LAM + ADV 
group (-0.81 vs  -0.47 log10 IU/mL, P  = 0.167), more 
patients in the LdT + ADV group had undetectable HBV 
DNA levels compared to those in the LAM + ADV group 
(30.2% vs  11.5%, P  = 0.019). Three patients with LdT 
+ ADV treatment and 2 patients with LAM + ADV treat-
ment achieved HBeAg loss. The patients in both groups 
tolerated the treatment well without serious adverse 
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events. The proportion of patients with estimated glo-
merular filtration rate ≥ 90 mL/min per 1.73 m2 in the 
LdT + ADV group increased from 49.1% (26/53) at 
baseline to 58.5% (31/53) at week 48, while that in the 
LAM + ADV group decreased from 37.7% (20/53) at 
baseline to 30.2% (16/53) at week 48.
CONCLUSION: The switch to LdT + ADV in subopti-
mal responders to LAM + ADV showed a significantly 
higher rate of virologic response at week 48. These 
results suggest that LdT + ADV could be a therapeutic 
option for patients who are unable to use enofovir diso-
proxil fumarate for any reason.
© 2013 Baishideng Publishing Group co., Limited. All rights 
reserved.
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Core tip: A suboptimal response is common in patients 
treated with lamivudine (LAM) + adefovir (ADV) com-
bination therapy and it has also become a new chal-
lenge for the management of chronic hepatitis B (CHB) 
patients. We commenced this study with the effect of 
telbivudine (LdT) + ADV combination therapy as a res-
cue therapeutic option in LAM-resistant CHB patients 
with suboptimal response to LAM + ADV. Our results 
demonstrated that switching from LAM + ADV to LdT + 
ADV resulted in superior virologic response, renoprotec-
tive effect and similar safety profiles at week 48. These 
results suggest that LdT + ADV could be a therapeutic 
option for patients who are unable to use enofovir diso-
proxil fumarate for any reason.
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INTRODUCTION
Worldwide, over 400 million people suffer from chronic 
hepatitis B (CHB). Patients with CHB have a 15%-40% 
life-time risk of  developing cirrhosis, hepatic decom-
pensation and hepatocellular carcinoma (HCC)[1,2]. High 
hepatitis B virus (HBV) DNA concentration in serum 
in patients with CHB is known as an independent risk 
factor for disease progression to cirrhosis and HCC[2,3]. 
Therefore, the treatment goal of  antiviral therapy for 
CHB is to achieve complete suppression of  viral replica-
tion as rapidly as possible[4-6], because prolonged viremia 
on therapy can lead to a higher risk of  future antiviral 
drug resistance and therapeutic failure as well as disease 
progression[2,7,8].
Lamivudine (LAM) has been widely used for treatment 
of  CHB since its first approval at 2002. However, a major 
limitation of  LAM is the development of  LAM-resistant 
YMDD-motif  mutations in the viral DNA polymerase, 
the prevalence of  which increases progressively to about 
70% after 4 years of  treatment[9]. In patients resistant 
to LAM, add-on combination therapy with LAM and 
adefovir (ADV) has resulted in lower rates of  virologic 
breakthrough and additional development of  genotypic 
resistance than when switching to ADV or entecavir[10,11]. 
Thus, LAM + ADV combination therapy has been recom-
mended as a rescue therapy in patients with LAM resistant 
viral strains in many Asian countries, for its considerable 
effectiveness, lower resistance and affordable price[5].
Unfortunately, a substantial proportion of  patients 
treated with LAM + ADV combination therapy show a 
suboptimal virologic response[10-12]. Because there has been 
evidence that this suboptimal response to antiviral therapy 
might have clinical relevance to higher risk of  developing 
resistance to long-term antiviral treatment, suboptimal 
response to nucleotide analogues (NAs), in addition to 
drug resistance, has also become a new challenge for the 
management of  CHB patients[13-15]. However, there is no 
standard optimal strategy for the management of  subop-
timal response to NA therapy at present. Many practice 
guidelines suggest a combination treatment regimen with 
tenofovir disoproxil fumarate (TDF) which is a NA with 
a high barrier to resistance as a highly potent rescue thera-
peutic option[4,6]. TDF, however, remains largely unavail-
able in Asian countries. Thus, several trials with various 
combination regimens for these populations have been 
proceeded[16,17], and the results suggested consistently that 
combination therapy rather than switching to another 
drug offers a potentially attractive therapeutic option. 
Telbivudine (LdT) is one of  the licensed NAs which is 
structurally related to LAM and highly selective for HBV 
DNA and inhibits viral DNA synthesis with no effect on 
human DNA or other viruses[18]. The Gestation Linked 
to Obesity and Environment (GLOBE), the largest trial 
in CHB, demonstrated that LdT is superior to LAM for 
all efficacy measures over 2 years of  therapy[19,20]. An-
other trial showed a superior viral suppressive effect of  
LdT even to ADV in treatment naïve CHB patients[21]. In 
addition, LDT + ADV combination treatment showed 
better outcomes against LAM-resistant HBV than ADV 
alone[22]. Therefore, LdT is a therapeutic option in LAM-
resistant hepatitis B patients with suboptimal response to 
LAM + ADV combination therapy.
In this study, we directly compared the antiviral effi-
cacy of  switching to LdT + ADV combination vs LAM + 
ADV continuation in hepatitis Be antigen (HBeAg) posi-
tive LAM-resistant hepatitis B patients who showed subop-
timal response to LAM + ADV combination treatment.
MATERIALS AND METHODS
Patients
Patients eligible for this study were men and women, aged 
over 20 years, positive for serum hepatitis B surface anti-
gen (HBsAg) for at least 6 mo, and positive for HBeAg. 
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Inclusion criteria were confirmed mutations in the 
HBV polymerase gene that confers resistance to LAM 
(rtM204V/I and/or rtL180M), and serum HBV DNA 
concentration > 12 IU/mL after combination treatment 
with LAM (100 mg/d) plus ADV (10 mg/d) for at least 
6 mo that was ongoing at the time of  randomization. Pa-
tients were expected to have well-preserved liver function 
(Child-Pugh score ≤ 6) and no history of  ascites, variceal 
bleeding, or encephalopathy.
Patients were excluded if  they had previous or current 
HCC; prior treatment with an antiviral agent other than 
LAM and/or ADV; coinfection with hepatitis C, hepatitis 
D, or human immune deficiency virus; concurrent sys-
temic corticosteroids or other immunosuppressive agents; 
history of  alcohol or substance abuse; or other current 
liver diseases, prior organ transplantation, or a history of  
malignancy within 3 years.
Study design
This was a randomized, active-control, open-label, single-
center, parallel trial. All eligible patients were enrolled 
in this study in Severance Hospital, Yonsei University 
College of  Medicine, Seoul, Korea, between March 
2010 and March 2011. Patients were randomized to 
either switching to LdT (600 mg/d orally) plus ADV 
(10 mg/d orally) (LdT + ADV group) or to continua-
tion with LAM (100 mg/d orally) plus ADV (10 mg/d 
orally) (LAM + ADV group), and were followed for 48 
wk. Randomized patients were evaluated at baseline and 
week 12, 24, 36 and 48. At each visit, hematology, bio-
chemistry, and prothrombin time/international normal-
ized ratio were assessed. HBV DNA level was measured 
at baseline and week 12, 24, 36 and 48, using a real-time 
Polymerase Chain Reaction assay (Abbott Laboratories, 
Chicago, IL) with a linear dynamic detection range of  12 
to 1 × 109 IU/mL. Multiplex Restriction fragment mass 
polymorphism (RFMP) assays of  the HBV genome were 
performed to detect LAM and ADV resistance mutations 
at baseline and at times as needed[23]. Because over 98% 
of  South Korean patients with CHB have HBV genotype 
C[24,25], HBV genotype was not determined. HBeAg and 
anti-HBeAb were assessed at baseline and at week 48, 
using commercially available enzyme immunoassays (Ab-
bott Laboratories)[26,27]. The upper limit of  normal (ULN) 
alanine aminotransferase (ALT) was defined as 40 IU/L. 
Occurrences of  adverse events were assessed at every 
visit through week 48.
The study was conducted in accordance with the 
ethical principles of  the Declaration of  Helsinki and the 
Guidelines for Good Clinical Practice as well as local 
regulatory requirements. This study was approved by the 
Institutional Review Board of  Yonsei University of  Med-
ical College, and written informed consent was obtained 
from all patients. This study was registered at ClinicalTri-
als.gov, number NCT01270165 (http://www.clinicaltrials.
gov/ct2/show/NCT01270165).
Study endpoints
The primary endpoint was the proportion of  patients in 
each treatment group who achieved virologic response (se-
rum HBV DNA concentration of  < 12 IU/mL) at week 
48. Secondary endpoints included mean reduction from 
baseline in serum HBV DNA concentration at week 48, 
the proportion of  patients with normalized serum ALT 
levels, HBeAg loss or seroconversion at week 48, and emer-
gence of  resistance mutation to drug during study period.
Statistical analysis
The variables were expressed as mean with SD or ranges, 
or n (%), as appropriate. The χ 2 or Fisher’s exact test and 
the Mann-Whitney U test were used to compare categori-
cal and continuous variables, respectively. Paired related 
data were analyzed using the Wilcoxon paired test. A two-
sided P value < 0.05 was considered to indicate statistical 
significance. All statistical analyses were performed with 
SPSS 18.0 (SPSS Inc., Chicago, IL, United States).
RESULTS
Baseline characteristics of patients
One hundred and ten patients were screened from March 
2010 to March 2011, and 106 were randomized (53 in 
each group). All patients completed 48 wk of  treatment 
after randomization; thus, data from all 106 patients ran-
domized were available for the intention-to-treat analysis 
(Figure 1).
Overall baseline characteristics of  all patients as 
well as of  each group are shown in Table 1. Twenty-
four (22.6%) patients had cirrhosis with well-preserved 
liver function. The mean (SD) serum HBV DNA levels 
was 3.71 (1.46) log10 IU/mL. The mean (ranges) dura-
tion of  LAM + ADV treatment prior to randomization 
was 17.1 (6-45) mo. At baseline, all patients had LAM 
resistance mutations, including 27 (25.5%) with rtM204I 
alone, 1 (0.9%) with rtM204I + rtM204V, 28 (26.4%) 
with rtM204I + rtL180M, 28 (26.4%) with rtM204V + 
rtL180M and 22 (20.8%) with rtM204I + rtM204V + 
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HBV DNA levels, drug-resistant mutations,
HBeAg status, liver biochemistry
12 wk    24 wk    36 wk   48 wk
LdT 600 mg + ADV 10 mg
once daily
LAM 100 mg + ADV 10 mg
once daily
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Figure 1  Flow diagram of study participants. LMA: Lamivudine; ADV: Adefo-
vir; LdT: Telbivudine; HBV: High hepatitis B virus; HBeAg: Hepatitis Be antigen.
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+ ADV groups are summarized and compared in Table 
2 and Figures 2-4. During treatment, the number of  
patients who achieved virologic response (serum HBV 
DNA level of  < 12 IU/mL) gradually increased to 16 
(30.2%) patients at week 48 in the LdT + ADV group. In 
contrast, the number of  patients with virologic response 
in the LAM + ADV group was consistently lower than 
those in the LdT + ADV group from week 12 to week 
48, and only 6 (11.5%) patients in the LAM + ADV 
group showed virologic response at week 48. The pri-
mary efficacy endpoint, the proportion of  patients who 
achieved HBV DNA level of  < 12 IU/mL at week 48, 
differed significantly between the two groups (30.2 % vs 
11.5 %, respectively, P = 0.019) (Figure 2 and Table 2).
Mean (SD) serum HBV DNA level of  the LdT + 
rtL180M. There were no genotypic mutations of  ADV in 
all patients at the baseline. Demographic and laboratory 
characteristics were similar between the two treatment 
groups, and mean (SD) serum HBV DNA levels in the 
LdT + ADV group and LAM + ADV group were 3.66 
(1.65) log10 IU/mL and 3.76 (1.25) log10 IU/mL, respec-
tively (P = 0.729). There was no difference in the mean 
duration of  prior LAM treatment as well as that of  LAM 
+ ADV treatment prior to randomization between the 
two groups (prior LAM period, 31.5 mo vs 33.5 mo, P = 
0.695; LAM + ADV period prior to randomization, 18.3 
mo vs 14.9 mo, P = 0.131).
Virologic response
The efficacy of  treatment in the LdT + ADV and LAM 
  Variables Total (n  = 106) LdT + ADV (n  = 53) LAM + ADV (n  = 53) P  value
  Mean age, yr   46.3 (22-76)    49.0 (23-76)     43.7 (22-73) 0.053
  Male   79 (74.5)    42 (79.2)     37 (69.8) 0.265
  Liver cirrhosis   24 (22.6)    13 (24.5)     11 (20.8) 0.647
  Laboratory results
     AST (IU/L)      29 (7-119)      33 (7-119)        28 (10-92) 0.125
     ALT (IU/L)        28 (13-125)      26 (15-84)          29 (13-125) 0.098
     Total bilirubin (mg/dL)       0.7 (0.3-1.8)        0.7 (0.3-1.8)         0.8 (0.3-1.6) 0.382
     Albumin (g/dL)       4.5 (0.7-5.4)        4.4 (3.4-5.4)         4.6 (0.7-5.1) 0.777
     Prothrombin time          1.01 (0.91-1.42)          1.00 (0.91-1.42)           1.02 (0.93-1.24) 0.917
     Platelet count (× 109/L)      175 (45-293)       175 (67-290)        174 (45-293) 0.610
     AFP (ng/mL)           2.87 (0.86-57.54)            2.61 (1.57-11.66)            2.98 (0.86-57.54) 0.030
  Mean prior LAM period, mo (range)   32.2 (8-139)  31.5 (8-77)       33.5 (11-139) 0.695
  Mean prior LAM + ADV period, mo (range) 17.1 (6-45) 18.3 (6-45)   14.9 (6-39) 0.131
  YMDD mutation 106 (100)   53 (100)       53 (100.0) -
     rtM204I alone   27 (25.5)    13 (24.5)     14 (26.4) 0.643
     rtM204I + rtM204V   1 (0.9)    1 (1.9)
     rtM204I + rtL180M   28 (26.4)    15 (28.4)     13 (24.5)
     rtM204V + rtL180M   28 (26.4)    12 (22.6)     16 (30.2) 0.501
  rtM204I + rtM204V + rtL180M   22 (20.8)    12 (22.6)     10 (18.9) 0.514
  eGFR (mL/min per 1.73 m2)           89.1 (56.1-131.6)           89.8 (59.8-131.6)            85.7 (56.1-123.3) 0.437
  Serum HBV DNA (log10 IU/mL) 0.729
     Mean (SD) 3.71 (1.46) 3.66 (1.65)  3.76 (1.25)
    Median (range)          3.63 (1.32-8.10)         3.34 (1.32-8.10)          3.78 (1.41-5.94)
Table 1  Baseline characteristics of patients  n  (%)
Data expressed as mean (SD), mean (range) or median (range). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; 
LAM: Lamivudine; ADV: Adefovire; HBV: High hepatitis B virus; eGFR: Estimated glomerular filtration rate; LdT: Telbivudine.
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ADV group was significantly lower than that of  the 
LAM + ADV group at week 12 and week 24 [3.05 (1.51) 
log10 IU/mL vs 3.84 (1.35) log10 IU/mL at week 12, P = 
0.011; 2.79 (1.52) log10 IU/mL vs 3.65 (1.44) log10 IU/mL 
at week 24, P = 0.003] (Table 2 and Figure 3). However, 
there was no statistically significant difference in serum 
HBV DNA levels between the LdT + ADV group and 
the LAM + ADV group [2.85 (1.73) log10 IU/mL vs 3.29 
(1.49) log10 IU/mL at 48 wk, P = 0.168] (Figure 3). 
The mean reduction of  serum HBV DNA levels 
from baseline to week 12 or week 24 was significantly 
greater in the LdT + ADV than in the LAM + ADV 
group (-0.68 log10 IU/mL vs 0.07 log10 IU/mL; P < 0.001, 
-0.88 log10 IU/mL vs -0.11 log10 IU/mL; P < 0.001, re-
spectively) (Figure 4 and Table 2). At week 48, however, 
there was no significant difference in the mean reduction 
of  serum HBV DNA from baseline between the LdT + 
ADV group and the LAM + ADV group (-0.81 log10 IU/
mL vs -0.47 log10 IU/mL, P = 0.167; Table 2 and Figure 4). 
 The number of  patients with virologic nonresponse, 
defined as < 1 log10 IU/mL reduction in serum HBV 
DNA level from baseline at week 24, was significantly 
lower in the LdT + ADV group than in the LAM + ADV 
group [33 (62.3%) vs 48 (90.6%), respectively, P = 0.001] 
(Table 2). A total of  8 patients experienced virologic 
breakthrough (≥ 1 log10 IU/mL increase in serum HBV 
DNA from nadir during treatment), 4 patients in the 
LdT + ADV group and 4 patients in the LAM + ADV 
group. Most of  them (6/8) had poor compliance for tak-
ing medication, and there was no new emergence of  drug 
resistance for LAM or ADV in the RFMP examination 
conducted at the time of  virologic breakthrough.
Biochemical and serologic response
The proportion of  patients with normal serum ALT 
levels at week 48 did not differ significantly between the 
LdT + ADV group and the LAM + ADV group (75.5% 
vs 71.7%, respectively; P = 0.768) (Table 2). Among pa-
tients with elevated ALT at baseline, the proportion of  
patients achieving normalized ALT at week 48 in the 
LdT + ADV group and LAM + ADV group were 57.1% 
(8/14) and 21.4% (3/14), respectively, and the difference 
showed borderline significance between the two groups (P 
= 0.053) (Table 2).
Three patients (5.7%) in the LdT + ADV group and 
2 patients (3.8%) in the LAM + ADV group became 
HBeAg negative at week 48 (P = 0.648; Table 2). No pa-
tient achieved loss of  HBsAg during the treatment period.
Safety
The majority of  patients in the LdT + ADV and LAM + 
ADV groups tolerated the treatment well without serious 
adverse events. No patient required dose reduction or 
discontinuation of  treatment due to an adverse event. No 
patient experienced ALT flare (> 10 × ULN), increased 
serum creatinine kinase level of  > 150 U/L, or serum 
phosphorus level of  < 1.5 mg/dL during the treatment 
period. Neither group reported decompensated cirrhosis 
or hepatocellular carcinoma from baseline to week 48.
No patient was found to have an elevation of  cre-
atinine ≥ 0.5 mg/dL. The mean estimated glomerular 
filtration rate (eGFR) is shown in Figure 5A. Although 
statistical significance did not exist, eGFR in the LdT + 
ADV group tended to increase during the treatment pe-
  Variables Week 12 P  value Week 24 P  value Week 48 P  value
LdT + ADV LAM + ADV LdT + ADV LAM + ADV LdT + ADV LAM + ADV
  Serum HBV DNA,
  mean (SD) (log10 IU/mL)
 3.05 (1.51)   3.84 (1.35)    0.011  2.79 (1.52)  3.65 (1.44)    0.003   2.85 (1.73)   3.29 (1.49) 0.168
  Reductions in HBV DNA1,   
  mean (SD) (log10 IU/mL)
-0.68 (0.83)   0.07 (0.60) < 0.001  -0.88 (1.06) -0.11 (0.85) < 0.001  -0.81 (1.43)  -0.47 (1.04) 0.167
  HBV DNA undetectable2        8 (15.1)     1 (1.9)    0.030      12 (22.6)     2 (3.8)    0.004      16 (30.2)        6 (11.5) 0.019
  Virologic nonresponders3 - - -      33 (62.3)     48 (90.6)    0.001 - - -
  HBsAg loss  0 (0)  0 (0) -   0 (0)  0 (0) -   0 (0)   0 (0) -
  HBeAg negativity,  0 (0)  0 (0) -      2 (3.8)  0 (0) -     3 (5.7)      2 (3.8) 0.648
  Normal range of ALT4     39 (73.6)     38 (71.7)    0.828      37 (69.8)     40 (75.5)    0.513     40 (75.5)      38 (71.7) 0.768
  ALT normalization5 2/14 (14.3) 6/14 (42.9)    0.209  6/14 (42.9) 5/14 (35.7)    0.704  8/14 (57.1)  3/14 (21.4) 0.053
Table 2  Virologic, serologic and biochemical responses during study periods  n  (%)
1Reduction of hepatitis B virus (HBV) DNA from baseline; 2Defined serum HBV DNA of < 12 IU/mL; 3Defined as a < 1 log10 IU/mL reduction in serum 
HBV DNA level from baseline at 24 wk; 4Upper normal limit of ALT, 40 IU/L; 5Among patients who have elevated ALT levels at baseline. ALT: Alanine 
aminotransferase; AST: Aspartate aminotransferase; LAM: Lamivudine; ADV: Adefovir. HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis Be antigen.
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Figure 4  Mean reduction of serum hepatitis B virus DNA levels from base-
line. Mean hepatitis B virus (HBV) DNA (log10 IU/mL) were plotted over time. 
Error bars indicate the standard deviation (aP value < 0.05). LAM: Lamivudine; 
ADV: Adefovire; LdT: Telbivudine.
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riod, whereas that in the LAM + ADV group tended to 
decrease. The proportion of  patients with eGFR ≥ 90 
mL/min per 1.73 m2 in the LdT + ADV group increased 
from 49.1% (26/53) at baseline to 58.5% (31/53) at week 
48, while that in the LAM + ADV group decreased from 
37.7% (20/53) at baseline to 30.2% (16/53) at week 48. 
The proportion of  patients with eGFR ≥ 90 mL/min 
per 1.73 m2 was significantly higher in the LdT + ADV 
group than in the LAM + ADV group at week 48 (58.5% 
vs 30.2%; P = 0.003) (Figure 5B). Twenty-six percent 
(7/27) of  the patients with baseline eGFR < 90 mL/min 
per 1.73 m2 shifted to eGFR ≥ 90 mL/min per 1.73 m2 
after 48 wk of  LdT + ADV treatment, as compared to 
15.2% (5/33) in the LAM + ADV group (P = 0.299).
DISCUSSION
This study is the first study that provides a direct com-
parison of  the antiviral efficacy of  LdT + ADV and 
LAM + ADV in HBeAg-positive LAM resistant CHB 
patients who have suboptimal response to LAM + ADV. 
The results of  this study show that treatment with LdT + 
ADV significantly suppressed HBV replication and more 
patients with LdT + ADV achieved virologic response 
compared to those with LAM + ADV after 48 wk of  
treatment. The difference in viral suppressive effect be-
tween the two groups was greatest at week 24, which de-
creased gradually thereafter.
The combination of  LAM and ADV has been rec-
ommended as a treatment option for patients with LAM 
resistant CHB[4-6]. Because of  the unavailability of  TDF 
in many Asian countries, ADV has been used widely as 
a combination treatment regimen. However, due to the 
weak antiviral activity of  ADV[28] and poor susceptibil-
ity for drug-resistant viral strains, suboptimal response 
is particularly common in patients who received LAM + 
ADV[29,30]. Evidence has shown that the persistence of  
suboptimal response during long-term antiviral treatment 
is associated with the emergence of  multi-drug resistant 
viral strains, which could result in poorer clinical out-
comes[31,32]. Thus, management of  a suboptimal response 
to antiviral therapy has recently been of  new concern, 
and combination with other NAs rather than switching 
to monotherapy offers a potentially attractive therapeutic 
option[33,34].
Based on the superior efficacy of  LdT over LAM 
shown in the GLOBE trial[35], a recent study examined 
switching patients who remained viremic under LAM 
treatment to LdT and demonstrated that early (≤ 24 wk) 
switch to LdT improves virologic outcomes in CHB pa-
tients with persistent viral replication under LAM treat-
ment[36]. In addition, previous two independent short-
term studies on patients with poor response to ADV 
monotherapy demonstrated that a higher proportion of  
patients in the LdT + ADV group achieved a virologi-
cal response at week 24 than did patients in the LAM + 
ADV group[37,38]. Based on these prior reports, we con-
ducted this study to investigate the efficacy of  switching 
to LdT + ADV as a substitute therapeutic option for 
patients who showed a suboptimal response to LAM + 
ADV combination treatment.
In our study, patients who were switched to LdT + 
ADV had a superior virologic response at 48 wk com-
pared to those who continued LAM + ADV treatment 
(30.2% vs 11.5%, P = 0.019). At 48 wk, the mean serum 
HBV DNA level was lower and the mean reduction from 
baseline was greater in the LdT + ADV group than in the 
LAM + ADV (2.85 log10 IU/mL vs 3.29 log10 IU/mL and 
-0.81 log10 IU/mL vs -0.47 log10 IU/mL, respectively), but 
the differences between the two groups were not statisti-
cally significant (P = 0.168 and P = 0.167, respectively). 
As described in Table 2, however, differences of  both the 
mean serum HBV DNA levels and the mean reduction 
of  HBV DNA levels from baseline were significant at 
12 wk and 24 wk. These results are ascribable to a differ-
ent rate of  decline in serum HBV DNA levels between 
the two groups. When we analyzed the rate of  decline 
between adjacent time points in the respective treatment 
groups, we found that there were no statistically signifi-
cant declines of  serum HBV DNA levels as times go by 
in the LAM + ADV group (Figure 6). Continuing LAM 
+ ADV with suboptimal response offers little antiviral 
benefit to patients with LAM-resistant HBV and as much 
as 90.6% of  patients who continued on LAM + ADV re-
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Figure 5  Estimated glomerular filtration rate over time in the two groups (A), and proportion of patients with estimated glomerular filtration rate ≥ 90 mL/
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mained as virologic non-responders (defined as < 1 log10 
IU/mL reduction in baseline serum HBV DNA level at 
24 wk) at week 24. In contrast, serum HBV DNA levels 
decreased significantly not only from baseline to 12 wk 
but also from 12 wk to 24 wk in the LdT + ADV group 
(P < 0.001 and P = 0.049, respectively) (Figure 6). This 
suggests that the viral suppressive effect emerged in the 
LdT + ADV group particularly during the early treatment 
period.
Considering the significantly decreased serum HBV 
DNA level in the LdT + ADV group during the early 
treatment period, we speculated the good virologic 
response in this group may be related to the effect 
of  LdT, because evidence in treatment-naïve patients 
demonstrates that LdT could significantly increase the 
rate of  virologic response compared to LAM as well as 
ADV[19,39,40]. However, the rate of  serum HBV DNA level 
decline in the LdT + ADV group decreased and became 
dull at the later part of  the study period, which is from 
week 24 to week 48. It might be correlated to diminished 
susceptibility to NAs and generally unsatisfying clinical 
outcomes in a pretreated population with drug-resistant 
HBV compared to a treatment-naïve population[41-43]. An-
other possible explanation is that the emergence of  ADV-
resistant HBV strains following suboptimal response to 
LAM + ADV might attenuate the superior viral suppres-
sive effect of  LdT to that of  LAM in these study patients. 
This is supported by a recent study which reported no 
differences in virologic and biochemical responses in the 
comparison of  two treatments, LdT + ADV and LAM + 
ADV, in CHB patients with suboptimal response to ADV 
monotherapy[44].
HBeAg loss is the key goal of  antiviral therapy for 
HBeAg-positive CHB patients, which indicates good 
prognosis, including lower rates of  cirrhosis and slower 
disease progression[5,6,45,46]. In our study, we reported quite 
low rates of  HBeAg loss, with 5.7% in the LdT + ADV 
group and 3.8% in the LAM + ADV group, suggesting 
that this pretreated population is particularly refractory to 
serologic response. It has been reported that HBeAg loss 
is less common in patients with LAM-resistant mutation 
than in those with wild-type HBV, regardless of  the ad-
equate rescue therapy[41-43].
Both treatments were well tolerated and showed simi-
lar safety profiles. Patients who switched from LAM + 
ADV to LdT + ADV did not experience any additional 
spectrum of  adverse effects. Interestingly, we found that 
the patients in the LdT + ADV group showed a favor-
able effect of  improved renal function compared to those 
in the LAM + ADV group during the treatment period. 
Although the mechanism has not been clarified, there 
have been several reports that LdT treatment is associat-
ed with renoprotective effects in patients with CHB[47,48]. 
Considering the risk of  renal impairment of  ADV, the 
renoprotective effect of  LdT could be complementary 
in patients who were treated with ADV for a long term 
period.
There are some limitations in this study. First, this 
prospective study has small sample size and a potential 
bias. Relatively short follow-up duration was another 
limitation. Thus, further well controlled studies with suf-
ficient size and longer duration of  follow-up are needed.
In conclusion, this trial demonstrated that switching 
from LAM + ADV to LdT + ADV in LAM-resistant 
CHB patients with suboptimal response resulted in supe-
rior virologic response, renoprotective effect and similar 
safety profiles at week 48. These results suggest that 
CHB patients with LAM-resistant HBV and suboptimal 
response to LAM + ADV treatment should be consid-
ered for switching to other combination regimens using 
more potent drugs. LdT + ADV could be a therapeutic 
option for patients who are unable to use TDF for any 
reason. However, a stronger rescue combination therapy 
should be investigated in this population.
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A substantial proportion of patients treated with lamivudine (LAM) + adefovir 
(ADV) combination therapy show a suboptimal virologic response. Because 
there has been evidence that this suboptimal response to antiviral therapy 
might have clinical relevance to higher risk of developing resistance to long-
term antiviral treatment, suboptimal response to nucleotide analogues, in addi-
tion to drug resistance, has also become a new challenge for the management 
of chronic hepatitis B (CHB) patients. However, there is no standard optimal 
strategy for the management of suboptimal response to nucleotide analogue 
therapy at present.
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Figure 6  Serial changes of mean serum hepatitis B virus DNA levels. Se-
rum hepatitis B virus DNA levels decreased significantly not only from baseline 
to 12 wk but also from 12 wk to 24 wk in the LdT + ADV group. LAM: Lamivu-
dine; ADV: Adefovire; HBV: High hepatitis B virus; LdT: Telbivudine.
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This study is the first study that provides a direct comparison of the antiviral ef-
ficacy of telbivudine (LdT) + ADV and LAM + ADV in hepatitis Be antigen-positive 
LAM resistant CHB patients who have suboptimal response to LAM + ADV.
Innovations and breakthroughs
Our results demonstrated that switching from LAM + ADV to LdT + ADV in LAM-
resistant CHB patients with suboptimal response resulted in superior virologic 
response, renoprotective effect and similar safety profiles at week 48.
Applications
From our study, it was suggested that LdT + ADV could be a therapeutic option 
for patients who are unable to use tenofovir disoproxil fumarate for any reason.
Peer review
The authors described a comparison of combination therapy of telbivudine plus 
adefovir vs lamivudine plus adefovir. This is the first comparison study about 
these 2 different combination therapies. This information is very important for 
future antiviral therapy of chronic B hepatitis. Furthermore, the study design is 
well organized and data is analyzed very well.
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